retatrutide autoimmune disease Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide vs Eloralintide Obesity Therapies

This significant difference shows that fatigue could be dose-dependent the higher the dose, the more likely you might feel tired

Weight may stabilize if nutrition and exercise are well managed

180+ Published studies, including 40+ randomized controlled trials 35+ Years of serving organizations across all industries and budgets #1 Doctor-recommended program for weight loss* Weight health that works for your organization The Weight Watchers comprehensive platform is built to help your people and your organization achieve weight health goals by providing comprehensive clinical services and scalable support every step of the way

Williams, S.T., et al